UR
VRTX icon

USCA RIA’s Vertex Pharmaceuticals VRTX Stock Holding History

USCA RIA’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$3.73M Buy
18,517
+6,522
+54% +$1.36M 0.23% 128
2021
Q1 		$2.58M Buy
11,995
+10,500
+702% +$2.31M 0.17% 174
2020
Q4 		$353K Buy
+1,495
New +$343K 0.02% 384

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

USCA RIA's VRTX Position: Q2 2021 in Review

USCA RIA increased its Vertex Pharmaceuticals (VRTX) stake by 54% in Q2 2021, buying an estimated $1.36M and bringing the position to 18,517 shares worth $3.73M. The position accounts for 0.23% of the portfolio, ranked #128.

USCA RIA first reported a position in VRTX in Q4 2020 and has held it in 3 quarters since. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

  • USCA RIA held 18,517 shares of Vertex Pharmaceuticals worth $3.73M as of Q2 2021.
  • USCA RIA bought 6,522 Vertex Pharmaceuticals shares in Q2 2021, an estimated $1.36M.
  • Vertex Pharmaceuticals made up 0.23% of USCA RIA's portfolio in Q2 2021, its #128 holding.
  • USCA RIA first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 3 quarters since.
  • 976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on USCA RIA's 13F filing for Q2 2021, filed 28 Jul 2021.